^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
REGIMENS FOR Ph-NEGATIVE ALL...Other Recommended Regimens...daunorubicin, vincristine, prednisone, pegaspargase, and cyclophosphamide (patients aged <60years), with rituximab for CD20-positive disease
Secondary therapy:
cyclophosphamide + vincristine + daunorubicin + pegaspargase
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Regimens for Ph-negative ALL: other recommended regimens… Hyper-CVAD: hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate and cytarabine; with rituximab for CD20-positive disease...linker 4-drug regimen: daunorubicin, vincristine, pegaspargase, and prednisone; with rituximab for CD20-positive disease.
Secondary therapy:
CVAD; cytarabine + methotrexate; vincristine + daunorubicin + pegaspargase
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Chronic Lymphocytic Leukemia)
New
Excerpt:
RITUXAN (rituximab) is a CD20-directed cytolytic antibody indicated for the treatment of...Adult patients with Chronic Lymphocytic Leukemia (CLL)...Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease

Excerpt:
...- CD20-positive disease...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer

Excerpt:
...- Histologically or immunophenotypically proven CD20-positive B-cell lymphoproliferative disorder...
Trial ID:
More C2 evidence
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Rituximab in Treating Young Patients Who Are Receiving Chemotherapy for B-Cell Non-Hodgkin's Lymphoma or B-Cell Acute Lymphoblastic Leukemia

Excerpt:
...- CD20 positive disease...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

Excerpt:
...- Diagnosis of CD20-positive ALL...
Trial ID:
Less C2 evidence
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study

Published date:
06/20/2023
Excerpt:
In the Ph-negative ALL group, patients with higher CD20 positivity experienced more favorable RFS (p < 0.001) and OS (p = 0.06) than those with lower CD20 positivity...The addition of rituximab to conventional chemotherapy for CD20-positive ALL is effective and tolerable.
Secondary therapy:
Chemotherapy
DOI:
10.3904/kjim.2022.401
Trial ID: